Epizyme (EPZM) Upgraded to “Hold” at ValuEngine

Epizyme (NASDAQ:EPZM) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Other equities analysts have also recently issued reports about the stock. Oppenheimer set a $26.00 price objective on shares of Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Tuesday, December 12th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Monday, October 16th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research report on Thursday, November 2nd. Finally, Jefferies Group restated a “buy” rating and issued a $25.00 price target on shares of Epizyme in a research report on Wednesday, January 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.73.

Epizyme (NASDAQ:EPZM) traded up $0.65 during mid-day trading on Tuesday, reaching $17.45. 284,477 shares of the company were exchanged, compared to its average volume of 494,972. The firm has a market cap of $1,160.00, a PE ratio of -7.69 and a beta of 2.19. Epizyme has a twelve month low of $9.30 and a twelve month high of $20.45.

In other Epizyme news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the transaction, the chief operating officer now directly owns 74,867 shares in the company, valued at approximately $1,245,038.21. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 25.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Fox Run Management L.L.C. acquired a new stake in shares of Epizyme during the third quarter worth $223,000. Tudor Investment Corp ET AL acquired a new stake in shares of Epizyme during the second quarter worth $215,000. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Epizyme during the third quarter worth $292,000. Teacher Retirement System of Texas acquired a new stake in shares of Epizyme during the fourth quarter worth $202,000. Finally, Bailard Inc. acquired a new stake in shares of Epizyme during the fourth quarter worth $251,000. Institutional investors own 85.99% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Epizyme (EPZM) Upgraded to “Hold” at ValuEngine” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/13/epizyme-epzm-upgraded-to-hold-at-valuengine.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply